Rewriting the rules for care of MDS and AML patients in the time of COVID-19. Academic Article uri icon

Overview

abstract

  • The care of patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has been radically altered by COVID-19, especially in New York City, the epicenter of the pandemic. Here we summarize how telemedicine, virtual visits, delayed transfusions, and chemotherapy, preferably selecting self-administered medications and visits by home healthcare workers, are employed to minimize exposure of our high-risk population of patients to the virus. The unique challenges of transplants during the pandemic and the consequences of an abrupt halt in all non-essential research activities are described. Not all the changes forced by COVID-19 are detrimental.

publication date

  • April 20, 2020

Identity

PubMed Central ID

  • PMC7169905

Scopus Document Identifier

  • 85083854846

Digital Object Identifier (DOI)

  • 10.1016/j.lrr.2020.100201

PubMed ID

  • 32318330

Additional Document Info

volume

  • 13